Leadership Expansion at IFLI in the Fight Against Follicular Lymphoma
Leadership Changes at the Institute for Follicular Lymphoma Innovation
DIAMOND BAR, Calif. — The Institute for Follicular Lymphoma Innovation (IFLI), a notable global non-profit dedicated to creating innovative treatment options for patients facing follicular lymphoma (FL), has recently appointed two dynamic individuals to its leadership team. Dr. Mehrdad Mobasher, M.D., M.P.H., and Dr. Carol O'Hear, M.D., Ph.D., are welcomed as Executive Partners, and their extensive experience promises to further IFLI’s mission.
Experience and Vision
David McCullagh, the Managing Director of IFLI, expressed high hopes for this new partnership, stating, "Carol and Mehrdad will be exceptional partners to the IFLI team and portfolio as they bring decades of strategic leadership and drug development expertise." His confidence stems from Dr. Mobasher's remarkable history of strategic development rooted in scientific excellence and Dr. O'Hear's track record as a physician-scientist with a focus on innovative therapy commercialization.
Dr. Mobasher possesses over twenty years of substantial experience in hematology and oncology. He previously served as Chief Medical Officer for Hematology at BeOne, previously known as BeiGene, where he played a pivotal role in expanding the drug zanubrutinib globally. He also worked with Zai Lab as Global Head of Late Stage Development, leading multiple oncology assets. His impressive career also includes vital roles at Corvus Pharmaceuticals and Genentech, where he contributed significantly to the development of venetoclax.
On joining IFLI, Dr. Mobasher remarked, "I am honored to join IFLI, an organization dedicated to advancing innovation for patients with follicular lymphoma. Collaborating with the team and ecosystem partners is an exciting opportunity to drive transformative therapies forward." His commitment to patient outcomes resonates deeply within IFLI’s core values.
Empowering Innovation in Bio-Pharmaceuticals
Dr. O'Hear complements this leadership enhancement with her rich experience in drug discovery and clinical development, currently serving as the SVP of Clinical Development and Chief Medical Officer at Exelixis. She has held significant roles at Gilead and Genentech, overseeing the clinical development programs of innovative drugs that target hematological and solid tumors.
Dr. O'Hear shared her enthusiasm about contributing to IFLI’s mission, stating, "Working with IFLI is an exciting opportunity to focus on what motivates me the most—identifying promising scientific discoveries and translating them into meaningful treatments for patients. I respect their commitment to impactful innovation and look forward to supporting novel therapies that can truly change lives." Her statement reinforces IFLI’s vision to drive substantial clinical advancements in treatments for FL.
About the Institute for Follicular Lymphoma Innovation
The Institute for Follicular Lymphoma Innovation is dedicated to fast-tracking innovative solutions for patients afflicted with follicular lymphoma. They are committed to supporting groundbreaking research aimed at developing new therapies and understanding the biology of FL. With funds allocated towards grants and partnerships, IFLI's goal is to enhance collaboration and facilitate knowledge sharing among researchers and institutions dedicated to FL.
This collaborative effort emphasizes IFLI's role as a mediator in advancing research and treatment options, striving for comprehensive solutions that address the needs of patients with follicular lymphoma.
Frequently Asked Questions
1. What is the main objective of IFLI?
IFLI aims to accelerate the development of innovative treatment options for patients with follicular lymphoma.
2. Who are the newly appointed Executive Partners at IFLI?
The newly appointed Executive Partners are Dr. Mehrdad Mobasher and Dr. Carol O'Hear.
3. What prior experience does Dr. Mobasher bring to IFLI?
Dr. Mobasher has over two decades of experience in hematology and oncology, overseeing strategic development and drug expansion in biopharmaceutical companies.
4. Why is Dr. O'Hear excited about joining IFLI?
She is motivated to identify scientific breakthroughs and translate them into effective treatments, emphasizing her respect for IFLI's innovative approach.
5. How does IFLI support FL research?
IFLI provides funding for grants and partnerships and promotes collaboration among researchers and institutions to advance FL research and treatment.
About The Author
Contact Riley Hayes privately here. Or send an email with ATTN: Riley Hayes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.